astrazeneca - Search News

China, AstraZeneca

AstraZeneca shareholders say they need clarity on China investigations

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue overhanging shares: an investigation of a top executive by authorities in China, one of its key markets.

Pharmaceutical Technology on … · 13h

AstraZeneca’s shares rise as it addresses China investigation

In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company confirmed that its Chinese business is under investigation for alleged unpaid import taxes on certain cancer drugs, including Imfinzi (durvalumab) and Imjudo (tremelimumab).

AstraZeneca offers some reassurance on China challenges

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more

AstraZeneca faces potential fines in China

FiercePharma · 20h

AstraZeneca warns of potential tax fines amid China sales slowdown, illegal drug importation probe

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities investigate the company’s former China head. | As AstraZeneca faces an ongoing investigation into alleged illegal importation of drugs in China,

Reuters on MSN · 1d

Drugmaker AstraZeneca flags possible $4.5 million Chinese tax fine

AstraZeneca could face a fine of up to $4.5 million in China over suspected unpaid taxes related to the import of two of its cancer drugs, the pharmaceuticals giant said on Thursday as it continues to gauge the impact of ongoing investigations in the key growth market.

This Is Money on MSN · 1d

AstraZeneca faces potential fines in China over unpaid import taxes

AstraZeneca said the taxes related to two cancer drugs, Imfinzi and Imjudo, and that it was continuing to co-operate with Chinese authorities.

21hon MSN

Peer demands answers on AstraZeneca deal collapse

Lord Storey says he fears Merseyside was "not a high priority" on the government's growth agenda.

1d

AstraZeneca CEO says company has no access to executive Wang, in detention in China

AstraZeneca has been approached a couple of times by Chinese authorities about their investigation into the drugmaker's ...

33m

AstraZeneca (AZN) Gets a Hold from Deutsche Bank

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on AstraZeneca (AZN – Research Report), with a ...

21hon MSN

AstraZeneca Boss Says UK ‘Isn’t the Worst Place’ to Invest

The boss of AstraZeneca Plc said he does not believe the UK is the worst place to invest, striking a conciliatory tone just ...

1don MSN

AstraZeneca Expects Further Sales, Earnings Growth After Results Beat Market Views

The pharmaceuticals major was boosted by high demand for its key drugs that offset a slight sales drop in China.

19h

AstraZeneca 'very disappointed' after scrapping £450m vaccine plant in Liverpool

Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision, which it revealed ...

4h

AstraZeneca PLC (AZN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges

AstraZeneca PLC (AZN) reports a robust 21% revenue increase for 2024, while navigating market challenges and strategic ...

Euronews (English) on MSN20h

AstraZeneca reports strong results boosted by promising trials

AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results